Pancreatitis in inflammatory bowel diseases

Journal of Clinical Gastroenterology

Volumn 44, Issue 4, 2010, Pages 246-253

  Pitchumoni, C S ^a,b,c   Rubin, Amy ^e   Das, Kiron ^d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b DREXEL UNIVERSITY   (United States)

^c SAINT PETER S UNIVERSITY HOSPITAL   (United States)

^d ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

IBD; Inflammatory bowel disease; Pancreatitis

Indexed keywords

ADALIMUMAB; AUTOANTIBODY; AZASAN; AZATHIOPRINE; BALSALAZIDE; BUDESONIDE; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; OLSALAZINE; PANCREAS ENZYME; SALAZOSULFAPYRIDINE; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ACUTE PANCREATITIS; AUTOIMMUNE PANCREATITIS; BONE MARROW SUPPRESSION; CHOLESTEROL STONE; CHRONIC PANCREATITIS; COMORBIDITY; CROHN DISEASE; DISEASE ASSOCIATION; DISULFIRAM LIKE REACTION; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DUODENUM; GALLSTONE; HUMAN; HYPERAMYLASEMIA; IMMUNOPATHOLOGY; INCIDENCE; LIVER INJURY; METALLIC TASTE; MORBIDITY; MORTALITY; NAUSEA; NEUTROPENIA; PANCREAS INSUFFICIENCY; PANCREATITIS; PERIPHERAL NEUROPATHY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS; URINE COLOR; URTICARIA; VOMITING;

6-MERCAPTOPURINE; ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MESALAMINE; PANCREATITIS; SULFASALAZINE;

EID: 77949957568     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181cadbe1     Document Type: Review

References (139)

1. Matsumoto T, Matsui T, Iida M, et al. Acute pancreatitis as a complication of Crohn,s disease. Am J Gastroenterol. 1989; 84:804-807.
2. Seyrig JA, Jian R, Modigliani R, et al. Idiopathic pancreatitis associated with inflammatory bowel disease. Dig Dis Sci. 1985;30:1121-1126.
3. Angelini G, Cavallini G, Bovo P, et al. Pancreatic function in chronic inflammatory bowel disease. Int J Pancreatol. 1988;3: 185-193.
4. SteinbergWM. Acute pancreatitis. In: Feldman M, Friedman LS, Brandt LJ. Sleisenger & Fordtran,s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 8th ed. Philadelphia, PA: Saunders Elsevier; 2006:1241.
5. Weber P, Seibold F, Jenss H. Acute pancreatitis in Crohn,s disease. J Clin Gastroenterol. 1993;17:286-291.
6. Moolsintong P, Loftus EV Jr, Chari ST, et al. Acute pancreatitis in patients with Crohn,s disease: clinical features and outcomes. Inflamm Bowel Dis. 2005;11:1080-1084.
7. Eisner TD, Goldman IS, McKinley MJ. Crohn,s disease and pancreatitis. Am J Gastroenterol. 1993;88:583-586.
8. Niemela S, Lehtola J, Karttunen T, et al. Pancreatitis in patients with chronic inflammatory bowel disease. Hepatogastroenterology. 1989;36:175-177.
9. Rasmussen HH, Fonager K, Sorensen HT, et al. Risk of acute pancreatitis in patients with chronic inflammatory bowel disease. A Danish 16-year nationwide follow-up study. Scand J Gastroenterol. 1999;34:199-201.
10. Barthet M, Hastier P, Bernard JP, et al. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am J Gastroenterol. 1999;94:2141-2148.
11. Meyers S, Greenspan J, Greenstein AJ, et al. Pancreatitis coincident with Crohn,s ileocolitis. Report of a case and review of the literature. Dis Colon Rectum. 1987;30:119-122.
12. Friedman S, Bank PA. Pancreatitis in inflammatory bowel disease. In: Bayless TM, Hanauer SB. Advanced Therapy of Inflammatory Bowel Disease. 2nd ed. Hamilton, Ontario: B.C. Decker, Inc; 2001:329-332.
13. Forsmark CE, Toskes PP. Acute pancreatitis. Medical management. Crit Care Clin. 1995;11:295-309.
14. Ball WP, Baggenstoss AH, Bargen JA. Pancreatic lesions associated with chronic ulcerative colitis. Arch Pathol (Chic). 1950;50:347-358.
15. Axon AT, Ashton MG, Lintott DJ. Chronic pancreatitis and inflammatory bowel disease. Clin Radiol. 1979;30:179-182.
16. Forbes D, Scott RB, Trevenen C, et al. Chronic pancreatitis associated with ulcerative colitis. Clin Invest Med. 1987; 10:321-324.
17. Lysy J, Goldin E. Pancreatitis in ulcerative colitis. J Clin Gastroenterol. 1992;15:336-339.
18. Andersson H, Bosaeus I, Fasth S, et al. Cholelithiasis and urolithiasis in Crohn,s disease. Scand J Gastroenterol. 1987; 22:253-256.
19. Lorusso D, Leo S, Mossa A, et al. Cholelithiasis in inflammatory bowel disease. A case-control study. Dis Colon Rectum. 1990;33:791-794.
20. Whorwell PJ, Hawkins R, Dewbury K, et al. Ultrasound survey of gallstones and other hepatobiliary disorders in patients with Crohn,s disease. Dig Dis Sci. 1984;29:930-933.
21. Kangas E, Lehmusto P, MatikainenM. Gallstones in Crohn,s disease. Hepatogastroenterology. 1990;37:83-84.
22. Hutchinson R, Tyrrell PN, Kumar D, et al. Pathogenesis of gall stones in Crohn,s disease: an alternative explanation. Gut. 1994;35:94-97.
23. Lapidus A, Bangstad M, Astrom M, et al. The prevalence of gallstone disease in a defined cohort of patients with Crohn,s disease. Am J Gastroenterol. 1999;94:1261-1266.
24. Fraquelli M, Losco A, Visentin S, et al. Gallstone disease and related risk factors in patients with Crohn disease: analysis of 330 consecutive cases. Arch Intern Med. 2001;161:2201-2204.
25. Bargiggia S, Maconi G, Elli M, et al. Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center. J Clin Gastroenterol. 2003;36:417-420.
26. Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology. 2007;45: 1267-1274.
27. Kratzer W, Haenle MM, Mason RA, et al. Prevalence of cholelithiasis in patients with chronic inflammatory bowel disease. World J Gastroenterol. 2005;11:6170-6175.
28. Jones MR, Gregory D, Evans KT, et al. The prevalence of gallbladder disease in patients with ileostomy. Clin Radiol. 1976;27:561-562.
29. Heaton KW, Read AE. Gall stones in patients with disorders of the terminal ileum and disturbed bile salt metabolism. Br Med J. 1969;3:494-496.
30. Cohen S, Kpplan M, Gottlieb L, et al. Liver disease and gallstones in regional enteritis. Gastroenterology. 1971;60: 237-245.
31. Dowling RH, Bell GD, White J. Lithogenic bile in patients with ileal dysfunction. Gut. 1972;13:415-420.
32. Rutgeerts P, Ghoos Y, Vantrappen G, et al. Biliary lipid composition in patients with nonoperated Crohn,s disease. Dig Dis Sci. 1986;31:27-32.
33. Gafa M, Sarli L, Miselli A, et al. Sludge and microlithiasis of the biliary tract after total gastrectomy and postoperative total parenteral nutrition. Surg Gynecol Obstet. 1987;165: 413-418.
34. Pitt HA, King W III, Mann LL, et al. Increased risk of cholelithiasis with prolonged total parenteral nutrition. Am J Surg. 1983;145:106-112.
35. Bolondi L, Gaiani S, Testa S, et al. Gall bladder sludge formation during prolonged fasting after gastrointestinal tract surgery. Gut. 1985;26:734-738.
36. Messing B, Bories C, Kunstlinger F, et al. Does total parenteral nutrition induce gallbladder sludge formation and lithiasis? Gastroenterology. 1983;84:1012-1019.
37. Damiao AO, Sipahi AM, Vezozzo DP, et al. Gallbladder hypokinesia in Crohn,s disease. Digestion. 1997;58:458-463.
38. Murray FE, McNicholas M, Stack W, et al. Impaired fattymeal- stimulated gallbladder contractility in patients with Crohn,s disease. Clin Sci (Lond). 1992;83:689-693.
39. Maurer P, Haag K, Roth M, et al. No evidence for abnormal gallbladder emptying in Crohn,s disease. Hepatogastroenterology. 1996;43:807-812.
40. Pereira SP, Bain IM, Kumar D, et al. Bile composition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment Pharmacol Ther. 2003;17:923-933.
41. Lapidus A, Einarsson C. Bile composition in patients with ileal resection due to Crohn,s disease. Inflamm Bowel Dis. 1998;4:89-94.
42. Brink MA, Slors JF, Keulemans YC, et al. Enterohepatic cycling of bilirubin: a putative mechanism for pigment gallstone formation in ileal Crohn,s disease. Gastroenterology. 1999;116:1420-1427.
43. Lapidus A, Akerlund JE, Einarsson C. Gallbladder bile composition in patients with Crohn ,s disease. World J Gastroenterol. 2006;12:70-74.
44. Sitzmann JV, Pitt HA, Steinborn PA, et al. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans. Surg Gynecol Obstet. 1990;170:25-31.
45. Frick TW, Speiser DE, Bimmler D, et al. Drug-induced acute pancreatitis: further criticism. Dig Dis. 1993;11:113-132.
46. Lankisch PG, Droge M, Gottesleben F. Drug induced acute pancreatitis: incidence and severity. Gut. 1995;37:565-567.
47. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol. 2005;39:709-716.
48. Eland IA, Van Puijenbroek EP, Sturkenboom MJ, et al. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol. 1999;94:2417-2422.
49. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf. 2000;23: 429-448.
50. Watkinson G. Sulphasalazine: a review of 40 years, experience. Drugs. 1986;32(suppl 1):1-11.
51. Poland GA, Love KR. Marked atypical lymphocytosis, hepatitis, and skin rash in sulfasalazine drug allergy. Am J Med. 1986;81:707-708.
52. Mihas AA, Goldenberg DJ, Slaughter RL. Sulfasalazine toxic reactions. Hepatitis, fever, and skin rash with hypocomplementemia and immune complexes. JAMA. 1978;239: 2590-2591.
53. Smith MD, Gibson GE, Rowland R. Combined hepatotoxicity and neurotoxicity following sulphasalazine administration. Aust N Z J Med. 1982;12:76-80.
54. Han T, Chawla PL, Sokal JE. Sulfapyridine-induced serumsickness- like syndrome associated with plasmacytosis, lymphocytosis and multiclonal gamma-globulinopathy. N Engl J Med. 1969;280:547-548.
55. Tisdale WA. Focal hepatitis, fever and skin rash following therapy with sulfamethoxypyridazine, a long-acting sulfonamide. N Engl J Med. 1958;258:687-690.
56. Faintuch J, Mott CB, Machado MC. Pancreatitis and pancreatic necrosis during sulfasalazine therapy. Int Surg. 1985;70:271-272.
57. Rubin R. Sulfasalazine-induced fulminant hepatic failure and necrotizing pancreatitis. Am J Gastroenterol. 1994;89: 789-791.
58. Garau P, Orenstein SR, Neigut DA, et al. Pancreatitis associated with olsalazine and sulfasalazine in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1994;18: 481-485.
59. Debongnie JC, Dekoninck X. Sulfasalazine, 5-ASA and acute pancreatitis in Crohn,s disease. J Clin Gastroenterol. 1994;19: 348-349.
60. Mallory A, Kern F Jr. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980;78:813-820.
61. Block MB, Genant HK, Kirsner JB. Pancreatitis as an adverse reaction to salicylazosulfapyridine. N Engl J Med. 1970;282:380-382.
62. Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289:491-495.
63. Klotz U, Maier KE. Pharmacology and pharmacokinetics of 5-aminosalicylic acid. Dig Dis Sci. 1987;32:46S-50S.
64. Fiorentini MT, Fracchia M, Galatola G, et al. Acute pancreatitis during oral 5-aminosalicylic acid therapy. Dig Dis Sci. 1990;35:1180-1182.
65. Keljo DJ, Sugerman KS. Pancreatitis in patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1997;25:108-112.
66. Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 1995;108:1427-1433.
67. Ransford RA, Langman MJ. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines. Gut. 2002;51:536-539.
68. Abdullah AM, Scott RB, Martin SR. Acute pancreatitis secondary to 5-aminosalicylic acid in a child with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1993;17:441-444.
69. Isaacs KL, Murphy D. Pancreatitis after rectal administration of 5-aminosalicylic acid. J Clin Gastroenterol. 1990;12: 198-199.
70. Tran K, Froguel E, Jian R, et al. Acute pancreatitis induced by mesalazine. J Clin Gastroenterol. 1991;13:715-716.
71. Deprez P, Descamps C, Fiasse R. Pancreatitis induced by 5-aminosalicylic acid. Lancet. 1989;2:445-446.
72. Sachedina B, Saibil F, Cohen LB, et al. Acute pancreatitis due to 5-aminosalicylate. Ann Intern Med. 1989;110:490-492.
73. Fernandez J, Sala M, Panes J, et al. Acute pancreatitis after long-term 5-aminosalicylic acid therapy. Am J Gastroenterol. 1997;92:2302-2303.
74. Toubanakis C, Batziou E, Sipsas N, et al. Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:933-934.
75. Inoue H, Shiraki K, Okano H, et al. Acute pancreatitis in patients with ulcerative colitis. Dig Dis Sci. 2005;50: 1064-1067.
76. Radke M, Bartolomaeus G, Muller M, et al. Acute pancreatitis in Crohn,s disease due to 5-ASA therapy. J Pediatr Gastroenterol Nutr. 1993;16:337-339.
77. Lees CW, Maan AK, Hansoti B, et al. Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008; 27:220-227.
78. Teml A, Schaeffeler E, Herrlinger KR, et al. Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing. Clin Pharmacokinet. 2007;46:187-208.
79. Herrlinger KR, Kreisel W, Schwab M, et al. 6-thioguanine- efficacy and safety in chronic active Crohn,s disease. Aliment Pharmacol Ther. 2003;17:503-508.
80. Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med. 1989;111: 641-649.
81. Warman JI, Korelitz BI, Fleisher MR, et al. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn,s disease and ulcerative colitis. J Clin Gastroenterol. 2003;37:220-225.
82. Singleton JW, Law DH, Kelley ML Jr, et al. National Cooperative Crohn,s Disease Study: adverse reactions to study drugs. Gastroenterology. 1979;77:870-882.
83. Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther. 2008;28:623-628.
84. Weersma RK, Peters FT, Oostenbrug LE, et al. Increased incidence of azathioprine-induced pancreatitis in Crohn,s disease compared with other diseases. Aliment Pharmacol Ther. 2004;20:843-850.
85. Floyd A, Pedersen L, Nielsen GL, et al. Risk of acute pancreatitis in users of azathioprine: a population-based casecontrol study. Am J Gastroenterol. 2003;98:1305-1308.
86. Cappell MS, Das KM. Rapid development of pancreatitis following reuse of 6-mercaptopurine. J Clin Gastroenterol. 1989;11:679-681.
87. Kawanishi H, Rudolph E, Bull FE. Azathioprine-induced acute pancreatitis. N Engl J Med. 1973;289:357.
88. Bank L, Wright JP. 6-Mercaptopurine-related pancreatitis in 2 patients with inflammatory bowel disease. Dig Dis Sci. 1984;29:357-359.
89. Haber CJ, Meltzer SJ, Present DH, et al. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology. 1986;91: 982-986.
90. Weersma RK, Batstra MR, Kleibeuker JH, et al. Are pancreatic autoantibodies associated with azathioprineinduced pancreatitis in Crohn,s disease? JOP. 2008;9: 283-289.
91. Freeman CD, Klutman NE, Lamp KC. Metronidazole. A therapeutic review and update. Drugs. 1997;54:679-708.
92. Finegold SM. Metronidazole. Ann Intern Med. 1980;93: 585-587.
93. Plotnick BH, Cohen I, Tsang T, et al. Metronidazole-induced pancreatitis. Ann Intern Med. 1985;103:891-892.
94. Sanford KA, Mayle JE, Dean HA, et al. Metronidazoleassociated pancreatitis. Ann Intern Med. 1988;109:756-757.
95. Celifarco A, Warschauer C, Burakoff R. Metronidazoleinduced pancreatitis. Am J Gastroenterol. 1989;84:958-960.
96. Corey WA, Doebbeling BN, DeJong KJ, et al. Metronidazole- induced acute pancreatitis. Rev Infect Dis. 1991;13: 1213-1215.
97. Sura ME, Heinrich KA, Suseno M. Metronidazole-associated pancreatitis. Ann Pharmacother. 2000;34:1152-1155.
98. Feola DJ, Thornton AC. Metronidazole-induced pancreatitis in a patient with recurrent vaginal trichomoniasis. Pharmacotherapy. 2002;22:1508-1510.
99. Nigwekar SU, Casey KJ. Metronidazole-induced pancreatitis. A case report and review of literature. JOP. 2004;5:516-519.
100. Tsesmeli NE, Giannoulis KE, Savopoulos CG, et al. Acute pancreatitis as a possible consequence of metronidazole during a relapse of ulcerative colitis. Eur J Gastroenterol Hepatol. 2007;19:805-806.
101. Friedman GD, Selby JV. How often does metronidazole induce pancreatitis? Gastroenterology. 1990;98:1702-1703.
102. Buchler M, Malfertheiner P, Friess H, et al. The penetration of antibiotics into human pancreas. Infection. 1989;17:20-25.
103. Kaplan MH, Dreiling DA. Steroids revisited. II. Was cortisone responsible for the pancreatitis? Am J Gastroenterol. 1977;67:141-147.
104. Caldarola V, Hassett JM, Hall AH, et al. Hemorrhagic pancreatitis associated with acetaminophen overdose. Am J Gastroenterol. 1986;81:579-582.
105. Prevost X, Myara I, Cosson C, et al. Asymptomatic hyperamylasemia after cyclosporine therapy in patients with renal transplants. Transplant Proc. 1988;20:555-558.
106. Spiess SE, Braun M, Vogelzang RL, et al. Crohn,s disease of the duodenum complicated by pancreatitis and common bile duct obstruction. Am J Gastroenterol. 1992;87:1033-1036.
107. Foutch PG, Ferguson DR. Duodenal Crohn,s disease complicated by common bile duct obstruction: report of a case and review of the literature. Am J Gastroenterol. 1984; 79:520-524.
108. Barnett SM, Davidson ED. Obstructive jaundice secondary to nonbiliary extrahepatic inflammatory disease. Am Surg. 1979; 45:618-620.
109. Nugent FW, Roy MA. Duodenal Crohn,s disease: an analysis of 89 cases. Am J Gastroenterol. 1989;84:249-254.
110. Legge DA, Hoffman HN II, Carlson HC. Pancreatitis as a complication of regional enteritis of the duodenum. Gastroenterology. 1971;61:834-837.
111. Pandol SJ, Saluja AK, Imrie CW, et al. Acute pancreatitis: bench to the bedside. Gastroenterology. 2007;132:1127-1251.
112. McCutcheon AD. A fresh approach to the pathogenesis of pancreatitis. Gut. 1968;9:296-310.
113. Shader AE, Paxton JR. Fatal pancreatitis. Am J Surg. 1966;111:369-373.
114. Yung K, Oviedo J, Farraye FA, et al. Ampullary stenosis with biliary obstruction in duodenal Crohn,s disease: a case report and review of the literature. Dig Dis Sci. 2005;50:1118-1121.
115. Barthelemy CR. Crohn,s disease of the duodenum with spontaneous reflux into the pancreatic duct. Gastrointest Radiol. 1983;8:319-320.
116. Meltzer SJ, Korelitz BI. Pancreatitis and duodenopancreatic reflux in Crohn,s disease. Case report and review of the literature. J Clin Gastroenterol. 1988;10:555-558.
117. Newman LH, Wellinger JR, Present DH, et al. Crohn,s disease of the duodenum associated with pancreatitis: a case report and review of the literature. Mt Sinai J Med. 1987;54:429-432.
118. Klein S, Greenstein AJ, Sachar DB. Duodenal fistulas in Crohn,s disease. J Clin Gastroenterol. 1987;9:46-49.
119. Creutzfeldt W, Lankisch PG. Acute pancreatitis: etiology and pathogenesis. In: Berk J, Haubrich W, Kalser M, et al, eds. Bockus Gastroenterology. 4th ed. Philadelphia: WB Saunders Co; 1985:3971-3992.
120. Das KM. Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis. Dig Dis Sci. 1999;44:1-13.
121. Koutroubakis IE, Drygiannakis D, Karmiris K, et al. Pancreatic autoantibodies in Greek patients with inflammatory bowel disease. Dig Dis Sci. 2005;50:2330-2334.
122. Fricke H, Birkhofer A, Folwaczny C, et al. Characterization of antigens from the human exocrine pancreatic tissue (Pag) relevant as target antigens for autoantibodies in Crohn,s disease. Eur J Clin Invest. 1999;29:41-45.
123. Torok HP, Folwaczny C. Pancreatic autoantibodies in Crohn,s disease: a feasible diagnostic tool? Eur J Gastroenterol Hepatol. 2005;17:37-39.
124. Seibold F, Weber P, Jenss H, et al. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn,s disease. Gut. 1991;32:1192-1197.
125. Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol. 2007;102:1042-1049.
126. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology. 1980;79:200-206.
127. Thompson HH, Pitt HA, Tompkins RK, et al. Primary sclerosing cholangitis: a heterogeneous disease. Ann Surg. 1982;196:127-136.
128. Chari ST. Diagnosis of autoimmune pancreatitis using its five cardinal features: introducing the Mayo Clinic,s HISORt criteria. J Gastroenterol. 2007;42(suppl 18):39-41.
129. Ichimura T, Kondo S, Ambo Y, et al. Primary sclerosing cholangitis associated with autoimmune pancreatitis. Hepatogastroenterology. 2002;49:1221-1224.
130. Saeki K, Hozawa S, Miyata N, et al. IgG4-negative autoimmune pancreatitis with sclerosing cholangitis and colitis: possible association with primary sclerosing cholangitis? Intern Med. 2008;47:943-948.
131. Chapin LE, Scudamore HH, Baggenstoss AH, et al. Regional enteritis: associated visceral changes. Gastroenterology. 1956; 30:404-415.
132. Toda N, Akahane M, Kiryu S, et al. Pancreas duct abnormalities in patients with ulcerative colitis: a magnetic resonance pancreatography study. Inflamm Bowel Dis. 2005; 11:903-908.
133. Hegnhoj J, Hansen CP, Rannem T, et al. Pancreatic function in Crohn,s disease. Gut. 1990;31:1076-1079.
134. Bregenzer N, Hartmann A, Strauch U, et al. Increased insulin resistance and beta cell activity in patients with Crohn,s disease. Inflamm Bowel Dis. 2006;12:53-56.
135. Forsmark CE, Baillie J. AGA Institute technical review on acute pancreatitis. Gastroenterology. 2007;132:2022-2044.
136. Heikius B, Niemela S, Lehtola J, et al. Elevated pancreatic enzymes in inflammatory bowel disease are associated with extensive disease. Am J Gastroenterol. 1999;94:1062-1069.
137. Bokemeyer B. Asymptomatic elevation of serum lipase and amylase in conjunction with Crohn,s disease and ulcerative colitis. Z Gastroenterol. 2002;40:5-10.
138. Grandval P, Barthet M, Desjeux A, et al. Pseudotumorous chronic pancreatitis associated with inflammatory bowel disease. Dig Dis Sci. 2001;46:898-900.
139. Maconi G, Dominici R, Molteni M, et al. Prevalence of pancreatic insufficiency in inflammatory bowel diseases. Assessment by fecal elastase-1. Dig Dis Sci. 2008;53:262-270.